Repositorio Dspace

RNA expression changes driven by altered epigenetics status related to NASH etiology

Mostrar el registro sencillo del ítem

dc.contributor.author Castellano-Castillo, Daniel
dc.contributor.author Ramos-Molina, Bruno
dc.contributor.author Frutos, María-Dolores
dc.contributor.author Arranz-Salas, Isabel
dc.contributor.author Reyes-Engel, Armando
dc.contributor.author Queipo-Ortuño, María-Isabel
dc.contributor.author Cardona, Fernando
dc.date.accessioned 2025-11-19T12:39:23Z
dc.date.available 2025-11-19T12:39:23Z
dc.date.issued 2024-05
dc.identifier.issn 0753-3322
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/21140
dc.description.abstract Non-alcoholic fatty liver disease (NAFLD) is a growing health problem due to the increased obesity rates, among other factors. In its more severe stage (NASH), inflammation, hepatocellular ballooning and fibrosis are present in the liver, which can further evolve to total liver dysfunction or even hepatocarcinoma. As a metabolic disease, is associated to environmental factors such as diet and lifestyle conditions, which in turn can influence the epigenetic landscape of the cells, affecting to the gene expression profile and chromatin organization. In this study we performed ATAC-sequencing and RNA-sequencing to interrogate the chromatin status of liver biopsies in subjects with and without NASH and its effects on RNA transcription and NASH etiology. NASH subjects showed transcriptional downregulation for lipid and glucose metabolic pathways (e.g., ABC transporters, AMPK, FoxO or insulin pathways). A total of 229 genes were differentially enriched (ATAC and mRNA) in NASH, which were mainly related to lipid transport activity, nuclear receptor-binding, dicarboxylic acid transporter, and PPARA lipid regulation. Interpolation of ATAC data with known liver enhancer regions showed differential openness at 8 enhancers, some linked to genes involved in lipid metabolism, (i.e., FASN) and glucose homeostasis (i.e., GCGR). In conclusion, the chromatin landscape is altered in NASH patients compared to patients without this liver condition. This alteration might cause mRNA changes explaining, at least partially, the etiology and pathophysiology of the disease.
dc.language.iso eng
dc.publisher ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
dc.rights Atribución-NoComercial-SinDerivadas 3.0 España
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/es/ *
dc.subject.mesh Humans
dc.subject.mesh Non-alcoholic Fatty Liver Disease/genetics/metabolism/pathology
dc.subject.mesh Epigenesis, Genetic
dc.subject.mesh Liver/metabolism/pathology
dc.subject.mesh Male
dc.subject.mesh Female
dc.subject.mesh Lipid Metabolism/genetics
dc.subject.mesh Middle Aged
dc.subject.mesh Chromatin/metabolism/genetics
dc.subject.mesh RNA/genetics
dc.subject.mesh Adult
dc.subject.mesh RNA, Messenger/genetics/metabolism
dc.subject.mesh Gene Expression Regulation
dc.title RNA expression changes driven by altered epigenetics status related to NASH etiology
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 38579398
dc.relation.publisherversion https://linkinghub.elsevier.com/retrieve/pii/S0753332224003925
dc.identifier.doi 10.1016/j.biopha.2024.116508
dc.journal.title Biomedicine & Pharmacotherapy
dc.identifier.essn 1950-6007


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta